Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Anastrozole Plus Fulvestrant Improved Survival in Metastatic Hormone Receptor-Positive Breast Cancer

February 13th 2012

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Peripheral Neuropathy Profile More Favorable With Eribulin

February 10th 2012

Patients with metastatic breast cancer who were treated with eribulin mesylate were less likely to experience peripheral neuropathy.

Role of Bisphosphonate Therapy Refined but Still More Questions

February 9th 2012

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

February 8th 2012

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Perez Describes Retesting Recurrent Breast Cancer

February 7th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Concurrent Zoledronic Acid Is Preferable in Letrozole-Treated Postmenopausal Patients With Breast Cancer

February 6th 2012

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Dr. Burris Discusses Targeting the mTOR Pathway

January 31st 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Fox Discusses Genomic Testing in Breast Cancer

January 27th 2012

Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer

Dr. Burstein on Pathological Complete Response

January 20th 2012

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

Dr. Vahdat Discusses the Side Effects of Halaven

January 18th 2012

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

HER2-Positive Patients Benefit From Combination Therapy of Trastuzumab and Lapatinib

January 17th 2012

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.

Dr. Perez Discusses Obesity as a Predictive Marker

January 16th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Obesity as a Predictive Marker

PARP Inhibition Explored in Triple-Negative Breast Cancer

January 16th 2012

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Tripathy on the Miami Breast Cancer Conference

January 12th 2012

Dr. Debu Tripathy, from USC Norris Comprehensive Cancer Center, on the Miami Breast Cancer Conference

NKTR 102 Will Move to a Phase III Trial in Pretreated Metastatic Breast Cancer

January 11th 2012

A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.

Dr. Hudis Discusses Axillary Lymph Node Status

January 10th 2012

Dr. Clifford Hudis, from Memorial Sloan-Kettering Cancer Center, Discusses Axillary Lymph Node Status

Breast Cancer Treatment Update

January 6th 2012

Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.

Overcoming Resistance to Endocrine Therapies

December 29th 2011

Patients with hormone receptor-positive metastatic breast cancer (MBC) frequently respond to multiple lines of endocrine therapy but, unfortunately, resistance eventually develops.